Introduction
============

The most prevalent primary liver cancer is known to be Hepatocellular carcinoma (HCC). It is considered to be the second highest cause of deaths associated with cancer globally [@B1], [@B2]. Chronic infections with the hepatitis B virus (HBV) or hepatitis C virus (HCV) are the primary risk factors for HCC [@B3]. In China, HBV plays a more prominent role because it may lead to liver fibrosis and cirrhosis, which eventually results in HCC [@B3]-[@B6]. Around 50% of HCC patients are associated with HBV infections [@B7]**.** Carriers of the hepatitis B surface antigen (HBsAg) are at 25-37-fold higher risk of developing HCC as compared to those not expressing the antigen [@B8], [@B9].

HBV contains eight known genotypes (A to H) [@B10]. Its genome contains four genes, C, P, S and X, that encode the core protein (HBcAg), DNA polymerase, surface antigen (HBsAg) and protein X (HBx), respectively. Numerous studies have been done to establish the mechanisms of HBV-associated hepatocarcinogenesis [@B11]-[@B14]. HBV genome integration, host gene deregulation and many viral factors have already been implied to contribute to HBV-associated HCC. HBx, for example, contributes to intracellular signal transduction, cell cycle and apoptosis regulation, and has been suggested to be an effector of hepatocarcinogenesis [@B11]. Almost 90% of HBx transgenic mice develop HCC [@B15]. HBV Integration leads to the dysfunction of host genes and affects cell proliferation, cell cycle progression, apoptosis, and even chromosomal stability [@B12], [@B16]-[@B20]. Recurrent integrations in *TERT* and *MLL4*, for example, are frequently observed in HCC [@B21]-[@B29]. HBx-LINE integration, which functions as a long non-coding RNA, has been shown to promote tumorigenesis of HCC [@B12]. With the help of next generation sequencing, it has been found that genome-wide HBV integration is commonly reported in HCC [@B25], [@B30].

HepG2.2.15 cells are derived from HepG2 with HBV expression stablely[@B31]. Little work has been done in the context of HepG2.2.15 cells with regards to the effects of HBV on cellular function, and HBV integration detection of HepG2.2.15 cells has not been carried out. In this study, we conducted HBV capture sequencing in HepG2.2.15 cells at both the whole genome and transcriptome levels, followed by RNA sequencing. Our results reveal that several genes are targets for HBV integration, leading to altered expression patterns of these genes. Integration in the dipeptidyl peptidase 7 (*DPP7*) gene causes decreased expression of *DPP7* in HepG2.2.15 cells. Furthermore, *DPP7* knockdown results in increased apoptosis with upregulation of the Bax/Bcl2 ratio. Our results suggest that HBV integration of DPP7 was involved in cell apoptosis.

Materials and Methods
=====================

Cell culture and transfection
-----------------------------

HepG2 was cultured with DMEM (HyClone, SH30022.01B) with 10 % FBS (Biological Industries) and incubated at 37℃ with 5% CO~2~. HepG2.2.15 was cultured with DMEM (HyClone) with 10 % FBS and 200ug/ml G418 (SIGMA). SiRNA transfection was done with Lipofection 3000 reagent according to the manufacturer\'s protocol. *DPP7* siRNA sequence 5\'-3\': siRNA\#1 (CCGAGCACUGCUACGACAUTT), siRNA\#2 (GCAACAAUGUGACCGAUAUTT), siRNA\#3 (CCUGAGUGCCUCAGUCAUCTT).

Antibody reagents
-----------------

Protein expression was analyzed by western blot. Rb, pRb780, pRb795, pRb807/811, cyclinD, cyclinE, CDK2, p21, p27, p53, Bcl2, Bax antibody were obtained from Cell Signaling Technology (CST). *DPP7* antibody was bought from Santa Cruz Biotechnology. GAPDH antibody was bought from Beyotime.

DNA and RNA isolation
---------------------

With the use of Genomic DNA Mini Kit (Invitrogen, Life Technologies) and Trizol reagent (Takara), extraction of Genomic DNA and Total RNA from cells were carried out, respectively. Then, quantification of DNA and RNA was carried out with the use of NanoDrop 2000.

HBV capture experiment at genomic DNA level
-------------------------------------------

Firstly, HBV capture probe were designed based on full-length HBV genome of eight types (A to H). The sequencing library construction was conducted as per Illumina protocol. Genomic DNA was sheared to 150-200 bp DNA fragments by Covaris E-210. They were purified, end blunted, "A" tailed, and finally ligated to adaptors. 12 cycle PCR was carried out to amplify the ligation products to build the genomic DNA library. Library quantification was analyzed by Qubit dsDNA HS Assay Kit (Invitrogen). Next, libraries hybridization with HBV probe was carried out at 65℃ for 24 hours. Uncaptured fragments were then removed by washing., The eluted fragments underwent amplification by 16 cycles of PCR to generate sequencing library followed by paired-end index sequencing in the illumina HiSeq 2000 sequencer.

HBV capture experiment at RNA level
-----------------------------------

Firstly, HBV capture probe were designed based on full-length HBV genome of eight types (A to H). As per Illumina paired-end sequencing protocols, 1 μg of total RNA was used to construct library. With ProtoScript® II Reverse Transcriptase (NEB), First-strand cDNA was synthesized. This was followed by second-strand cDNA synthesis with the help of Second Strand Synthesis Enzyme Mix (NEB) and purified using DNA Clean & Concentrator kit (Zymo Research). The double-strand cDNA products were sheared to 150-200 bp DNA fragments by Covaris E-210. These sheared fragments underwent purification, end blunting, "A" tailing, and finally ligation to adaptors. 12 cycles of PCR amplification were conducted for library construction. Libraries quantification was analyzed by Qubit dsDNA HS Assay Kit (Invitrogen). Then, library hybridization with HBV probe were conducted at 65℃ for 24 hours. Uncaptured fragments were removed by washing. Sequencing libraries were obtained by amplification of eluted fragments with 16 cycles of PCR, and were then subjected to paired-end index sequencing in the illumina HiSeq 2000 sequencer.

Viral-Human Fusion identification by VirusSeq
---------------------------------------------

VirusSeq [@B32] was used to detect viral-human fusion. Briefly, sequencing raw data was firstly filtered, so that clean reads could be obtained for subsequent analysis. The clean PE reads were then mapped onto both the human genome (NCBI build 37, HG19) and HBV genome (HE815465.1) by Burrows-Wheeler Aligner (BWA). hg19Virus is a novel hybrid reference genome made by combining human genome (H19) and virus genome (Virus). All PE reads are mapped to hg19Virus. Only the PE reads that mapped to both human chromosome and Virus, is considered as a discordant read pair. After annotation with human and viral genes, fusion candidates were reported for further analysis as previously reported [@B32]. The coverage, depth and coverage rate onto HBV genome were measured according to reported reads.

PCR and Sanger sequencing validation
------------------------------------

For verification of the HBV integration breakpoints from VirusSeq analysis, Sanger sequencing was conducted. Using the paired-end assembled fragment as a basis, the PCR primers (Table [S1](#SM0){ref-type="supplementary-material"}) were designed, that one of the primers was located in HBV genome and the other in human genome. PCR was then carried out followed by sequencing.

Detection of HBV gene copy number
---------------------------------

HBV gene copy number was detected using Diagnostic Kit for Quantification of Hepatitis B Virus DNA based on manufacturer\'s protocol. Finally, PCR reactions of the prepared samples were performed with Stepone Real-Time PCR System.

Cell proliferation analysis
---------------------------

We used Cell Counting Kit-8 (CCK-8, Biotool) for analysis of cell proliferation based on manufacturer\'s instruction. Cells were seeded in 96-well plates at a density of 3.5×10^3^ cells per well and cultured in DMEM with 10% serum. 24h/48h/72h later, the old medium was removed, and then 1/10 volume of CCK-8 was then added into 100ul fresh medium. After incubation at 37℃ for 4h, absorbance was measured at 450 nm.

Cell cycle analysis
-------------------

We used Cell Cycle and Apoptosis Analysis Kit (Beyotime) to analyze cell cycle based on manufacturer\'s protocol. Cells (1×10^6^) with different treatments were harvested followed by washing with cold 1 × PBS. Cells were then fixed in 1 ml 70 % cold ethanol at 4 ℃ for one night. Cells were washed three times with cold 1 × PBS, and then resuspended in 500 ul staining buffer (200 mg/ml RNase A and 50 μg/ml PI) and stained in the dark at 37 ℃ for 30min. Finally, Flow Cytometer (ACEA NovoCyte^TM^) was used for cell cycle detection.

Cell apoptosis analysis
-----------------------

We used Annexin V-FITC/PI apoptosis kit (Multi Science) to analyze cell apoptosis based on manufacturer^\'^s protocol. Cells (5 × 10^5^) with different treatments were harvested followed by washing with cold 1 × PBS. The cell were resuspended in 500ul 1 × Binding Buffer, and 5 μl Annexin V-FITC and 10 μl PI were then added to the cell mixture followed by incubation in the dark at 37 ℃ for 5 minutes. Finally, apoptosis was detected by Flow Cytometer (ACEA NovoCyte^TM^).

RNA extraction, reverse transcription and qPCR
----------------------------------------------

We used Trizol (Takara) to extract RNA from cells. cDNA synthesis was conducted by PrimeScript^TM^ RT Master Mix kit (Takara). PCR reaction was then done with SYBR Premix Ex Taq^TM^, (Tli RNaseH Plus) kit (Takara). The primers used in this paper were shown in Table [S2](#SM0){ref-type="supplementary-material"}. GAPDH was used as a control gene.

Statistics
----------

Data were presented as mean ± SEM based on three independent experiments. Unpaired student\'s t test analysis was performed in quantification of RT-PCR results. *p* values that were less than 0.05 were considered to be statistically significant.

Results
=======

Detection of HBV in HepG2.2.15 cells
------------------------------------

HBV DNA was detected in HepG2.2.15 cells by a fluorescent labeled PCR probe. HepG2 cell was served as a negative control. As shown in Figure [1](#F1){ref-type="fig"}A, the HBV DNA copy number in HepG2.2.15 cells showed a 25,763-fold increase in comparison with HepG2, confirming that HepG2.2.15 cells are positive for HBV DNA.

Identification of genome HBV integration sites
----------------------------------------------

To explore the integration of the HBV genome in HCC, we conducted HBV capture sequencing in HepG2.2.15 cells using the Illumina HiSeq 2000 sequencing system. Identification of the integrated HBV genome was subsequently performed using VirusSeq [@B32] (Figure [2](#F2){ref-type="fig"}).

We obtained 2,374,482 raw reads that had with a 141 bp average read length from HepG2.2.15 genomic DNA samples, of which 192,901 reads were matched to the HBV genome (HBV-D-3) (Table [1](#T1){ref-type="table"}). An average depth of 6417.52 and 100% coverage was achieved with 20-fold read mapped to the HBV genome (Table [1](#T1){ref-type="table"}). 14 HBV integration breakpoints were identified (Table [1](#T1){ref-type="table"}), and the genome HBV integration breakpoints in HepG2.2.15 were distributed in HBV genome (Figure [1](#F1){ref-type="fig"}B).

As shown in Table [2](#T2){ref-type="table"}, 14 HBV integration breakpoints are mainly located within the region where the X protein, S protein and core protein are located [@B33]. The HBx protein is the most frequently integrated protein. HBV is preferentially integrated into chromosome 1 (4/14), chromosome 2 (3/14), chromosome 3 (2/14), chromosome 7 (1/14), chromosome 9 (1/14), chromosome 20 (1/14), chromosome 21 (1/14) and chromosome X (1/14) (Table [2](#T2){ref-type="table"}). The majority of HBV integrations are intronic and intergenic, while the *DPP7* integration sites are exonic (Table [2](#T2){ref-type="table"}).

Identification of transcriptome HBV integration sites
-----------------------------------------------------

To further explore HBV integration at the level of the transcriptome, total RNA of HepG2.2.15 cells was obtained, reversed transcribed to cDNA and subjected to HBV capture sequencing (Figure [2](#F2){ref-type="fig"}).

We obtained 94,192,016 raw reads with an average read length of 138 base pairs. A total of 561,510 reads were matched to the HBV genome (HBV-D-3) (Table [1](#T1){ref-type="table"}). We obtained 100% coverage of the targeted region with 20-fold read mapped to the HBV genome (Table [1](#T1){ref-type="table"}). Nine HBV integration breakpoints were identified (Table [1](#T1){ref-type="table"}), and the transcriptome HBV integration breakpoints in HepG2.2.15 were distributed in HBV genome (Figure [1](#F1){ref-type="fig"}B).

As shown in Table [3](#T3){ref-type="table"}, all nine HBV integration breakpoints are distributed in the region where the X protein and S protein are located within the HBV genome [@B33] (Table [3](#T3){ref-type="table"}). Three integration breakpoints are within the S protein and six are within the X protein. The HBV integration sites are located within chr1, chr3, chr5, chr7, chr9, chr11, chr12, chr17 (Table [3](#T3){ref-type="table"}). Most of the integrations are intronic and intergenic, while the HBV integration of *DPP7* is exonic (Table [3](#T3){ref-type="table"}).

Expression of target genes with HBV integration
-----------------------------------------------

To explore whether HBV integration affects the expression of host genes, we conducted RNA-Seq in HepG2 and HepG2.2.15 cells. Statistical analysis of RNA-Seq data is shown in Table [4](#T4){ref-type="table"}. Expression change of genes were shown in Figure [1](#F1){ref-type="fig"}C, including the genes without or with HBV integration in genome level, transcriptome level and both genome and transcriptome level. Combining the RNA-Seq and HBV integration results, four genes (*CAMSAP2/CCDC12/DPP7/OR4F3*) are identified with HBV integration in both the genome and transcriptome of HepG2.2.15 cells (Table [5](#T5){ref-type="table"}). Expression of *DPP7*, which shows integration of the X protein transcript, decreases 4.8-fold as compared to expression in HepG2 cells. Changes in expression levels of *CAMSAP2/CCDC12/OR4F3*, which show intronic or intergenic HBV integration, are lower (Table [5](#T5){ref-type="table"}). To confirm HBV integration into the genes, PCR amplification followed by Sanger sequencing was carried out. Integration of HBV into the four genes (*CAMSAP2/CCDC12/DPP7/OR4F3*) was confirmed by Sanger sequencing (Figure [S1](#SM0){ref-type="supplementary-material"}), validating the results from HBV capture sequencing.

HBV integration decreases cell proliferation, and induces G1 arrest and apoptosis
---------------------------------------------------------------------------------

Since HepG2.2.15 cells originate from HepG2 with HBV expression stablely, we first examined whether the cell phenotype is stable. The cell proliferation assay shows a significant reduction of HepG2.2.15 cells growth rate as compared to HepG2 cells (Figure [3](#F3){ref-type="fig"}A). Cell cycle analysis was conducted to determine whether cell cycle distribution was changed. As compared to HepG2 cells, there was an obvious increase in the proportion of G1 phase and a decrease in the S and G2 phases in HepG2.2.15 cells (Figure [3](#F3){ref-type="fig"}B, C). The decreased cell proliferation and G1 cell cycle arrest are consistent with previous reports [@B34]. Cell apoptosis detection was also carried out by flow cytometry, and the rate of apoptosis in HepG2.2.15 cells is increased in comparison with HepG2 (Figure [3](#F3){ref-type="fig"}D, E).

To identify the mechanism of G1 cell cycle arrest, expression of cell cycle-regulated genes were detected. The results obtained from RT-PCR showed that mRNA expression of Rb, cyclin D1, cyclin E1, p21, p27, and p53 is increased in HepG2.2.15 cells, while expression of *CDK2* is decreased (Figure [4](#F4){ref-type="fig"}A) in comparison with HepG2 cells. In addition, the protein expression of Rb, cyclin D1, cyclin E1, p21, p27, p53 is upregulated, while there was a downregulation of *CDK2* expression in HepG2.2.15 cells (Figure [4](#F4){ref-type="fig"}B).

*DPP7* knockdown results in cell apoptosis
------------------------------------------

In order to determine whether the phenotype of HepG2.2.15 cells is linked with HBV integration, we studied *DPP7*, since it is the only gene with HBV integration at both the genome and transcriptome levels, and decreased expression levels. The mRNA expression of *DPP7* is 10-fold decrease in HepG2.2.15 in comparison with HepG2 (Figure [4](#F4){ref-type="fig"}A).

*DPP7*, also referred to as quiescent cell proline dipeptidase (QPP, DPP2, DPPII), is a post-proline cleaving aminopeptidase [@B35], [@B36]. It has been previously reported that *DPP7* inhibition in quiescent lymphocytes results in cell apoptosis [@B37]. We reasoned that the HBV integration-mediated decreases in *DPP7* expression may be associated with cell apoptosis in HepG2.2.15 cells. Therefore, we used *DPP7* siRNAs for knockdown of *DPP7* (Figure [4](#F4){ref-type="fig"}C). In HepG2 cells, *DPP7* knockdown induced more cell apoptosis than the siRNA control (Figure [4](#F4){ref-type="fig"}D). Apoptosis-related proteins such as Bcl2 and Bax play an vital role in cell apoptosis. We then analyzed the expression of apoptosis-related proteins to explore the cellular mechanism of the higher apoptosis of HepG2.2.15 cells. Western blot results show that *DPP7* knockdown results in an upregulation of Bax, without affecting Bcl2 (Figure [4](#F4){ref-type="fig"}E). This leads to an increase in Bax/Bcl2 ratio, which may contribute to the increased levels of apoptosis.

Discussion
==========

Currently, HCC is the second leading cause of cancer-associated deaths globally. In China, HBV has a vital contribution to HCC development. The HepG2.2.15 originates from HepG2 by stable transfection with HBV genome [@B31]. In comparison with HepG2, HepG2.2.15 shows decreased proliferation, G1 cell cycle arrest and increased rate of apoptosis. In our study, HBV capture sequencing was conducted at both the genome and transcriptome levels to discover HBV integration sites in the HepG2.2.15 genome. RNA-Seq was subsequently performed to analyze gene expression. Based on the HBV capture sequencing and RNA-Seq results, a number of genes show HBV integration accompanied by altered expression. In particular, integration of HBV into *DPP7* is observed both at the genome and transcriptome levels, and expression of this gene is reduced in HepG2.2.15 cells when compared to HepG2 cells. Furthermore, *DPP7* knockdown leads to apoptosis with upregulation of the Bax/Bcl2 ratio in HepG2 cells, which suggest that HBV integration-induced decreases in *DPP7* expression can increase apoptosis in HepG2.2.15 cells, indicating that HBV can regulate cell function through integrating into host genes.

Previous studies have revealed a large number of genes with HBV integration in human HCC tissue [@B30]. Although a large amount of data has been obtained in studies of clinical samples, few studies have performed functional analysis. The mechanism by which HBV integration induces HCC remains to be elucidated. One of the challenges in identifying these mechanisms is that HBV was randomly integrated into the genome, which makes choosing a cell line model with specific HBV integration difficult. HBx-LINE1, an HBV-human chimeria contribute to HCC through acting as a LncRNA [@B12]. In the aforementioned study, six HCC cell lines were obtained from patients who were infected with HBV, which paves the way for further functional studies [@B12]. Here, we chose HepG2.2.15 cells as our HBV integration cell model, to explore the relationship between HBV integration and cell function and phenotype.

In a previous study, whole-genome gene expression were profiled in both HepG2 and HepG2.2.15 cells. It showed that 2978 genes are up- or down-regulated, including genes related to cell cycle, transport, signal transduction, cell adhesion and cellular metabolism [@B38]. Two-dimensional gel electrophoresis-mass spectrometry indicated that HBV infection can affect protein expression [@B39], [@B40]. HepG2.2.15 cells also show reduction in proliferation and G1 cell cycle arrest with alterations in cell cycle-regulated genes [@B34], [@B41], [@B42]. However, the association between HBV integration and cell functional and phenotypic changes has not been elucidated. In our study, HepG2.2.15 cells showed reduction in proliferation, G1 cell cycle arrest and increased apoptosis when compared to HepG2 cells. HBV capture sequencing and RNA-Seq revealed that HBV integration occurs in *DPP7* accompanied by decreased expression levels of the gene. *DPP7*, a post-proline cleaving aminopeptidase, has been shown to play role in apoptosis of lymphocytes [@B37]. Consistent with this finding, we show that *DPP7* knockdown leads to increased apoptosis with upregulation of the Bax/Bcl2 ratio in HepG2 cells. Together, our data suggests that HBV integration affects the expression of host genes such as *DPP7*, leading to increased apoptosis in HepG2.2.15 cells.

Although our results reveal alterations of several important genes, it has some limitations. For example, many genes have been identified with HBV integration in HCC tissue, whereas fewer genes were detected here, which may be attributed to the cell model we choose. Since HepG2.2.15 cells originate from HepG2 with HBV expression stablely, they do not exactly mimic the HBV infection process under physiological conditions. In this regard, HepG2.2.15 may not be the best cell line model for HBV integration analysis. Nevertheless, this cell line provides a tool to study HBV integrations and the effects on expression of host genes. Our results suggest that HBV infection decreases host cell activities, such as decreased cell proliferation, and increased cell apoptosis, which are contrary to the predominant hypothesis that HBV infection contributes to hepatocarcinogenesis [@B4]-[@B6]. HBV contains eight genotypes (A-H) with different geographic distribution. Increasing evidence has suggested that not all HBV genotypes are linked with HCC [@B43], [@B44]. The HBV genotype of HepG2.2.15 cells is genotype D, [@B31] and the clinical impact of genotype D is still controversial. For example, some clinical and epidemiological data suggests that genotype D does not affect the severity and chronicity of the disease [@B45], while other studies report that genotype D is related to chronic and occult HBV infections [@B46]. In these previous studies, a large amount of data was obtained from clinical specimens and, therefore, more functional studies are needed to clarify these issues. It is possible that the decreased cell proliferation and cell activity induced by HBV integration in HepG2.2.15 is specific for HBV genotype D, as previously reported [@B34].
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![**HBV integration breakpoints distribution in HBV genome and gene expression change in HepG2.2.15.** (A) Detection of HBV gene copy number by PCR. (B) Distribution of integration breakpoints in the HBV genome in HepG2.2.15 (genome integration breakpoints of HepG2.2.15: blue, transcriptome integration breakpoints of HepG2.2.15: red) are shown. Histograms were constructed for 100bp intervals. HBV genes with different functions are shown. (C) Volcano plot of differently expressed genes between HepG2.2.15 and HepG2. The logarithms of the fold changes of genes (x-axis) are plotted against the negative logarithm of their p-value(y-axis). Black dots represent genes without HBV integration (No integration), blue dots represent genes with HBV integration in genome (DNA integration), green dots represent genes with HBV integration in transcriptome (RNA integration), red dots represent genes with HBV integration in both genome and transcriptome (DNA&RNA integration).](jcav10p4142g001){#F1}

![**The pipeline of workflow.** Experimental workflow and bioinformatic analysis is performed in this study. BWA: Burrows-Wheeler Aligner.](jcav10p4142g002){#F2}

![**HepG2.2.15 cells show decreased proliferation, G1 cell cycle arrest and increased apoptosis.** (A) Proliferation of HepG2 and HepG2.2.15 cells. OD450 values were measured at 24 h, 48 h, 72 h and 96h. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001). (B) Cell cycle analysis of HepG2 and HepG2.2.15 cells. (C) Quantitative cell cycle distribution of HepG2 and HepG2.2.15 cells. HepG2.2.15 cells show G1 cell cycle arrest when compared to HepG2 cells. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001, NS: none significant). (D) Analysis of cell apoptosis by flow cytometry. Increased apoptosis is observed in HepG2.2.15 cells. (E) Quantitative results of cells undergoing apoptosis in HepG2 and HepG2.2.15 populations. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001).](jcav10p4142g003){#F3}

![**DPP7 knockdown induces cell apoptosis in HepG2 cells** (A) RT-PCR analysis of cell cycle regulated genes in HepG2 and HepG2.2.15 cells. GAPDH was used as a reference gene. Data shown represents the mean ± SEM values from three independent experiments (\*p \< 0.05, \*\*\*p \< 0.001). (B) Western blot analysis of cell cycle regulated genes. Quantification results were shown in the right. GAPDH was used as a reference gene. Data shown represents the mean ± SEM values from three independent experiments (\*\*p\<0.01, \*\*\*p \< 0.001). (C) Verification of *DPP7* siRNA knockdown efficiency by RT-PCR and western blot. Quantification results were shown in the upper. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001). (D) Knockdown of *DPP7* induces increased cell apoptosis in HepG2 cells. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001). (E) Knockdown of *DPP7* in HepG2 cells leads to increased Bax/Bcl2 ratio as measured by western blot. Quantification results were shown in the right. GAPDH served as a loading control. Data shown represents the mean ± SEM values from three independent experiments (\*\*\*p \< 0.001).](jcav10p4142g004){#F4}

###### 

HBV capture sequencing data

  Sample        Reads number   Raw bases (Mb)   Clean bases (Mb)   Average read length   No. of the reads mapped to HBV   Target 20X rate (%)   Target mean depth   Coverage rate (%)   No. of integration breakpoints
  ------------- -------------- ---------------- ------------------ --------------------- -------------------------------- --------------------- ------------------- ------------------- --------------------------------
  Genomic DNA   2374482        358.55           316.91             141                   192901                           100                   8157.27             100                 14
  Total RNA     94192016       14222.99         12390.66           138                   561510                           100                   22604.45            100                 9

###### 

HBV genomic integration breakpoints and gene expression fold change

  Human location   Nearest genes   Location type   HBV location   HBV transcript         Supporting reads number   Nearest gene fold change (log2)
  ---------------- --------------- --------------- -------------- ---------------------- ------------------------- ---------------------------------
  chr1:155104681   EFNA1           intronic        460            S protein              14                        -0.693
  chr1:200809469   CAMSAP2         intronic        1746           X protein              8                         -0.923
  chr3:47015291    CCDC12          intronic        1820           X protein              71                        0.023
  chr9:140008668   DPP7            extronic        1716           X protein              114                       -2.261
  chr2:27241835    MAPRE3          intronic        1829           X protein              11                        -2.092
  chr1:200809321   CAMSAP2         intronic        1746           precore/core protein   10                        -0.923
  chr1:569999      OR4F3           intergenic      1801           precore/core protein   13                        \-
  chr7:25573057    NPVF            intergenic      1594           X protein              103                       0
  chr3:42696821    ZBTB47          intronic        1829           X protein              112                       -2.59583
  chrX:9148656     FAM9B           intergenic      2082           precore/core protein   55                        -6.74895
  chr20:62935214   LINC00266-1     intergenic      2639           polymerase protein     38                        3.4362
  chr2:27775260    GCKR            intergenic      2775           polymerase protein     22                        6.90382
  chr21:10007085   TEKT4P2         intergenic      607            S protein              45                        1.28415
  chr2:27915039    SLC4A1AP        intronic        2567           polymerase protein     22                        1.17871

Chr: chromosome; -: no signal test.

###### 

HBV RNA integration breakpoints and gene expression fold change

  Human location   Nearest gene   Location type   HBV location   HBV transcript   Supporting reads number   Nearest gene log2(fold change)
  ---------------- -------------- --------------- -------------- ---------------- ------------------------- --------------------------------
  chr11:85195011   DLG2           intronic        407834         S protein        9                         1.283
  chr5:71146794    MAP1B          intergenic      408128         S protein        8                         4.212
  chr17:33478111   UNC45B         intronic        407658         S protein        6                         -1.162
  chr1:200809476   CAMSAP2        intronic        409112         X protein        12                        -0.923
  chr3:47015261    CCDC12         intronic        409144         X protein        41                        0.023
  chr9:140008690   DPP7           exonic          409079         X protein        359                       -2.261
  chr7:25572926    MIR148A        intergenic      408983         X protein        16                        0.003
  chr1:570051      OR4F3          intergenic      409270         X protein        8                         \-
  chr12:20704358   PDE3A          intronic        408967         X protein        7                         -9.627

Chr: chromosome; -: no signal test.

###### 

Statistics information of RNA-seq data

  Sample       Reads number   Raw bases (Mb)   Clean bases (Mb)   Average read length   Average insert size   Mapped reads   Coverage rate(%)   Target mean depth
  ------------ -------------- ---------------- ------------------ --------------------- --------------------- -------------- ------------------ -------------------
  HepG2        193531404      29223.24         25439.31           130                   948.7                 96922102       62.76              59.55
  HepG2.2.15   145773306      22011.77         19359.6            126                   989.9                 98707630       61.12              65.79

###### 

HBV integration genes in both genome and transcriptome

  Gene      Chr    HBV transcript           Integration type   fold change (log2)
  --------- ------ ------------------------ ------------------ --------------------
  CAMSAP2   chr1   X protein/core protein   intronic           -0.923
  CCDC12    chr3   X protein                intronic           0.023
  DPP7      chr9   X protein                exonic             -2.261
  OR4F3     chr1   X protein/core protein   intergenic         \-

Chr: chromosome; -: no signal test.
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